特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
613119

世界の抗結核治療薬市場:薬剤クラス別、エンドユーザー別、地域別 - 成長、動向、予測

Anti-tuberculosis Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 112 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.58円
世界の抗結核治療薬市場:薬剤クラス別、エンドユーザー別、地域別 - 成長、動向、予測
出版日: 2020年08月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 112 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の抗結核治療薬市場は2018~2023年にかけCAGR6.0%となる見通しです。結核に対する認知度の高まりから、北米が同市場を独占しています。

当レポートでは、世界の抗結核治療薬市場について調査し、市場の概要と成長動向、競合動向、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響因子

第5章 市場概要

  • 現在の市場シナリオ
  • ポーターズファイブフォース分析

第6章 促進因子、阻害因子、機会、課題分析

  • 促進因子
  • 阻害因子
  • 市場機会
  • 課題

第6章 市場セグメンテーション

  • 薬剤クラス別
  • エンドユーザー別
    • 病院・クリニック
    • 政府機関
    • 非営利団体
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合環境

  • 合併・買収
  • 協定、連携、提携
  • 新製品上市

第9章 主要企業

  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lupin Pharmaceuticals Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi
  • その他

第10章 市場の将来

目次
Product Code: 55411

Factors, such as rising prevalence of tuberculosis, growing initiative from government organization for tuberculosis awareness, collaboration between academic and private players for novel drug development, and rising incidence of MDR and XDR cases in developing countries, are propelling the growth of the market studied.

According to the WHO's 2020 Global Tuberculosis (TB) Report, a total of 1.5 million people died from TB in 2018. Worldwide, TB is one of the top 10 causes of death and the leading cause from a single infectious agent. Overall, the global burden of TB and MDR-TB is a challenge for leading medical regulatory institutions. The active interest of both medical communities and government alike, in curbing TB, is expected to increase the number of diagnoses for TB. This is, in turn, driving the growth of the global anti-tuberculosis therapeutics market, supported by the increasing global prevalence of TB and MDR-TB.

Key Market Trends

Hospitals/Clinics are Expected to Witness the Fastest Growth in the Coming Future

The WHO's strategy to prevent TB includes engaging all relevant healthcare providers in tuberculosis (TB) care, while control through public-private mix approach remains an essential component of the strategy. The TB prevalence rate is more in countries, like China, India, and Africa, hence, the governments of these respective countries are trying to decrease the rate by increasing government initiatives and the number of hospitals.

As per 2019 Global Tuberculosis Report by the WHO, developing countries accounted for most of the global total TB cases, including India (27%), China (9%), Indonesia (8%), and the Philippines (6%). The developing countries mostly rely on the hospitals for healthcare access. Hence high incidence in the regions will boost the market in hospitals and clinics.

Asia-Pacific is Expected to be the Largest Market Over the Forecast Period

As per 2019 Global Tuberculosis Report by the WHO, geographically, most TB cases in 2018 were in the WHO regions of South-East Asia (44%), Africa (24%) and the Western Pacific (18%). As a result, a large number of cases are found in the Asia-Pacific region, which is expected to help the region dominate the market. Moreover, most of the global pharmaceutical companies have penetrated in developing countries like India and China, which is also expected to increase the availability of therapeutics and boost the market growth.

Competitive Landscape

The anti-tuberculosis therapeutics market is highly consolidated, with very few companies holding a substantial market share. With the rising focus of the healthcare sector on the development of novel drugs and the growing investment in the R&D, imore small to mid-sized companies are estimated to enter into the market in the coming future.

Currently, companies such as Lupin, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, and Johnson and Johnson hold the largest market share.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Tuberculosis
    • 4.2.2 Growing Initiative from Government Organization for Tuberculosis Awareness
    • 4.2.3 Rising Incidence of MDR and XDR Cases in Developing Countries
  • 4.3 Market Restraints
    • 4.3.1 Adverse Side Effects of Anti-tuberculosis Drugs
    • 4.3.2 High Cost of MDR and XDR TB Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Isoniazid
    • 5.1.2 Rifampin
    • 5.1.3 Ethambutol
    • 5.1.4 Pyrazinamide
    • 5.1.5 Fluoroquinolones
    • 5.1.6 Bedaquiline
    • 5.1.7 Amynoglycosides
    • 5.1.8 Thioamides
    • 5.1.9 Cyclic Peptides
    • 5.1.10 Other Drug Classes
  • 5.2 By End User
    • 5.2.1 Hospitals and Clinics
    • 5.2.2 Government Agencies
    • 5.2.3 Non Profit Organizations
    • 5.2.4 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Lupin Limited
    • 6.1.2 Macleods Pharmaceuticals Ltd
    • 6.1.3 Otsuka Pharmaceutical Co. Ltd
    • 6.1.4 Johnson and Johnson
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Novartis AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.